The FluMist vaccine, manufactured by AstraZeneca, had previously been approved back in 2003 to be given by health care ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

The overall effectiveness of 70% is better than most flu vaccines ... While the Pfizer vaccine is already being rolled out, the Oxford-AstraZeneca one has a crucial advantage - its vials can ...

The FDA has started a review of an extension to the labelling for AstraZeneca’s influenza ... FluMist could become the first self-administered flu vaccine in the US, opening up a new avenue ...

AstraZeneca (AZ) has taken an $80 million hit after US authorities said its nasal flu vaccine should not be used. The Advisory Committee on Immunization Practices of the Centers for Disease ...

More than one in two Irish parents say their child missed schools days in the past year due to flu or flu-like symptoms with ...

Andrew Berens gave his rating based on several factors, including AstraZeneca’s strong financial performance in the third quarter of 2024. The company reported total revenues of $13.565 billion, ...

There will be a delay in some batches of nasal-spray flu vaccine being delivered to schools in England, it has been announced. Public Health England said some schools would need to reschedule ...

The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007 ... FluMist is officially the first ...